Doctors Note Logo

Published on: 1/9/2026

What is gemtesa used for?

Gemtesa (vibegron) is an FDA-approved prescription medication for overactive bladder (OAB) in adults. It works by relaxing the bladder muscle, helping reduce urinary urgency, frequent urination, urge-related leakage, and nighttime bathroom trips.

Key factors to consider include candidacy, how quickly Gemtesa starts working, common side effects (such as headache, nausea, or diarrhea), drug interactions, and safety precautions for people with certain conditions like high blood pressure or kidney/liver issues. Full details are outlined below to help guide your next steps.

Not sure if your symptoms point to overactive bladder or something else? Understanding the root cause is the first step toward effective treatment—and guessing can delay relief. Take a free, instant, and confidential symptom check to clarify what may be causing your urinary symptoms and get personalized guidance on what to do next.

Reviewed for medical accuracy: 07/09/2026

answer background

Explanation

What Is Gemtesa Used For?

Gemtesa (generic name: vibegron) is a prescription medication approved to treat symptoms of overactive bladder (OAB) in adults. OAB is a common condition characterized by a sudden urge to urinate, frequency (needing to go often), and sometimes leakage (urge urinary incontinence). Gemtesa belongs to a class of drugs called β3-adrenoceptor agonists and works by relaxing the bladder muscle, helping it hold more urine and reducing the urge to go.


How Gemtesa Works

  • Gemtesa selectively stimulates β3-adrenoceptors in the bladder's detrusor muscle.
  • Activation of these receptors leads to muscle relaxation during the bladder's storage phase.
  • This relaxation increases bladder capacity and reduces involuntary contractions that cause urgency.

Who Might Benefit from Gemtesa?

Gemtesa is prescribed for adults who experience one or more of the following OAB symptoms:

  • Urgency: A sudden, difficult-to-control need to urinate.
  • Frequency: Needing to urinate eight or more times in 24 hours.
  • Urgency Urinary Incontinence: Leakage of urine following a strong urge.
  • Nocturia: Waking at night one or more times to urinate.

Gemtesa may be considered when behavioral interventions (e.g., bladder training, fluid management) are not sufficient alone.


Clinical Evidence: Efficacy and Safety

A pivotal study by Seki et al. (2018) evaluated the efficacy and safety of vibegron (Gemtesa) in adults with OAB:

  • Study design: Randomized, double-blind, placebo-controlled.
  • Participants: Adults reporting OAB symptoms for ≥3 months.
  • Duration: 12 weeks of once-daily dosing.

Key findings:

  • Significant reduction in daily micturitions (urination episodes) compared to placebo.
  • Fewer urgency episodes and incontinence incidents.
  • Improved quality of life scores.
  • Safety profile similar to placebo; most common side effects were headache and common cold symptoms.

These results support Gemtesa as an effective and well-tolerated option for OAB.


Common Side Effects

Most people tolerate Gemtesa well. Common side effects observed in clinical trials include:

  • Headache
  • Nasopharyngitis (common cold)
  • Back pain
  • Constipation

Most side effects were mild to moderate. If any side effect feels severe or does not go away, contact your healthcare provider.


Important Safety Information

Before starting Gemtesa, tell your doctor if you:

  • Have significant liver problems.
  • Are pregnant, planning to become pregnant, or breastfeeding.
  • Are taking other medications or supplements.

Gemtesa is not recommended for children under 18. Always follow your doctor's dosing instructions.


Using Gemtesa: What to Expect

  • Dosage: One 75 mg tablet taken by mouth once daily with or without food.
  • Onset of Effect: Some patients notice improvement within 2–4 weeks; full benefit may take up to 12 weeks.
  • Missed Dose: If you miss a dose, take it as soon as you remember unless it's almost time for your next dose. Do not take two doses at once.
  • Follow-up: Your doctor may schedule follow-up visits to monitor response and adjust treatment if needed.

Lifestyle and Behavioral Strategies

Combining Gemtesa with lifestyle changes can further improve OAB symptoms:

  • Maintain a bladder diary to track fluid intake and urination patterns.
  • Practice bladder training (gradually increasing the interval between bathroom visits).
  • Perform pelvic floor muscle exercises (Kegels) to strengthen support muscles.
  • Limit bladder irritants (e.g., caffeine, alcohol, spicy foods).
  • Stay hydrated with moderate fluid intake spread throughout the day.

When to Seek Medical Attention

While Gemtesa is generally safe, certain situations require prompt medical evaluation:

  • Sudden inability to urinate (urinary retention)
  • Severe abdominal pain, fever, or chills
  • Blood in the urine
  • Signs of an allergic reaction (rash, itching, swelling, difficulty breathing)

If you experience any of these, seek medical care right away.


Free Online Symptom Checker

If you're experiencing urgency, frequency, or other bladder concerns and want to understand your symptoms better, use Ubie's free AI-powered Overactive Bladder Symptom Checker to receive personalized insights in just 3 minutes and prepare for your doctor's appointment with confidence.


Discuss with Your Doctor

This information is not a substitute for professional medical advice. Always speak to your doctor or a qualified healthcare professional about:

  • Any new or worsening symptoms
  • Whether Gemtesa is right for you
  • Potential interactions with other medications
  • Any concerns about side effects

If you suspect a serious or life-threatening condition, seek immediate medical attention.

Talk to your doctor to determine if Gemtesa is the right treatment for your overactive bladder and to develop a comprehensive plan tailored to your needs.

(References)

  • Seki N, Hattori K, Takahashi S, Kishida S, Agawa T, Watanabe T. (2018). Efficacy and safety of vibegron, a β3-adrenoreceptor agonist… Int J Urol, 29182164.

  • Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Garcia-Pagán JC. (2007). Hepatic venous pressure gradient predicts development… Journal of Hepatology, 17848471.

  • Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. (2016). Portal hypertension and variceal bleeding: unresolved issues… Journal of Hepatology, 27393628.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.